Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 213 articles:
HTML format

Single Articles

    July 2021
  1. KASHIMA Y, Shibahara D, Suzuki A, Muto K, et al
    Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer.
    Cancer Res. 2021 Jul 9. pii: 0008-5472.CAN-20-2811.
    PubMed     Abstract available

  2. VON ITZSTEIN MS, Gerber DE, Minna JD
    Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers.
    Cancer Res. 2021;81:3441-3443.
    PubMed     Abstract available

    June 2021
  3. LI HJ, Ke FY, Lin CC, Lu MY, et al
    ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-mesenchymal transition.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3543.
    PubMed     Abstract available

  4. ISHIOKA K, Yasuda H, Hamamoto J, Terai H, et al
    Upregulation of fibroblast growth factor 9 in lung adenocarcinoma transdifferentiation to small cell lung cancer.
    Cancer Res. 2021 Jun 3. pii: 0008-5472.CAN-20-4048.
    PubMed     Abstract available

    May 2021
  5. DENEKA AY, Kopp MC, Nikonova AS, Gaponova AV, et al
    Nedd9 restrains autophagy to limit growth of early stage non-small cell lung cancer.
    Cancer Res. 2021 May 18. pii: 0008-5472.CAN-20-3626.
    PubMed     Abstract available

  6. WANG C, Meng X, Zhou Y, Yu J, et al
    Long noncoding RNA CTD-2245E15.3 promotes anabolic enzymes ACC1 and PC to support non-small cell lung cancer growth.
    Cancer Res. 2021 May 3. pii: 0008-5472.CAN-19-3806.
    PubMed     Abstract available

    April 2021
  7. MUSOLF AM, Simpson CL, Moiz BA, Pikielny CW, et al
    Genetic variation and recurrent haplotypes on chromosome 6q23-25 risk locus in familial lung cancer.
    Cancer Res. 2021 Apr 14. pii: 0008-5472.CAN-20-3196.
    PubMed     Abstract available

  8. LI R, Salehi-Rad R, Crosson W, Momcilovic M, et al
    Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-deficient Non-Small Cell Lung Cancer.
    Cancer Res. 2021 Apr 14. pii: 0008-5472.CAN-20-3564.
    PubMed     Abstract available

    March 2021
  9. ANCEY PB, Contat C, Boivin G, Sabatino S, et al
    Glut1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy.
    Cancer Res. 2021 Mar 22. pii: 0008-5472.CAN-20-2870.
    PubMed     Abstract available

  10. YANG Z, Liang SQ, Yang H, Xu D, et al
    CRISPR-mediated kinome editing prioritizes a synergistic combination therapy for FGFR1-amplified lung cancer.
    Cancer Res. 2021 Mar 8. pii: 0008-5472.CAN-20-2276.
    PubMed     Abstract available

  11. WANG X, Ricciuti B, Nguyen T, Li X, et al
    Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer.
    Cancer Res. 2021 Mar 2. pii: 0008-5472.CAN-20-3991.
    PubMed     Abstract available

  12. KONEN JM, Rodriguez BL, Padhye A, Ochieng JK, et al
    Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Cancer Res. 2021;81:1398-1412.
    PubMed     Abstract available

  13. DAI M, Boudreault J, Wang N, Poulet S, et al
    Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Cancer Res. 2021;81:1332-1346.
    PubMed     Abstract available

    February 2021
  14. SIN TK, Zhang G, Zhang Z, Zhu JZ, et al
    Cancer-Induced Muscle Wasting Requires p38beta MAPK Activation of p300.
    Cancer Res. 2021;81:885-897.
    PubMed     Abstract available

  15. DAGNINO S, Bodinier B, Guida F, Smith-Byrne K, et al
    Prospective identification of elevated circulating CDCP1 in patients years before onset of lung cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-3454.
    PubMed     Abstract available

  16. DAVENPORT ML, Echols JB, Silva AD, Anderson JC, et al
    miR-31 displays subtype specificity in lung cancer.
    Cancer Res. 2021 Feb 8. pii: 0008-5472.CAN-20-2769.
    PubMed     Abstract available

  17. SCHAFF DL, Singh S, Kim KB, Sutcliffe MD, et al
    Fragmentation of Small-cell Lung Cancer Regulatory States in Heterotypic Microenvironments.
    Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1036.
    PubMed     Abstract available

  18. BOSHUIZEN J, Pencheva N, Krijgsman O, D'Empaire Altimari D, et al
    Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade.
    Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-0434.
    PubMed     Abstract available

  19. HILFENHAUS G, Mompeon A, Freshman J, Prajapati DP, et al
    A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier.
    Cancer Res. 2021;81:619-633.
    PubMed     Abstract available

  20. CRESSWELL GM, Wang B, Kischuk EM, Broman MM, et al
    Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cancer Res. 2021;81:671-684.
    PubMed     Abstract available

  21. ROSSI G, Barabino E, Fedeli A, Ficarra G, et al
    Radiomic Detection of EGFR Mutations in NSCLC.
    Cancer Res. 2021;81:724-731.
    PubMed     Abstract available

    January 2021
  22. ZHU M, Huang Y, Bender ME, Girard L, et al
    Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
    Cancer Res. 2021 Jan 25. pii: 0008-5472.CAN-20-2808.
    PubMed     Abstract available

  23. MONTEVERDE T, Sahoo S, La Montagna M, Magee P, et al
    CKAP2L promotes non-small cell lung cancer progression through regulation of transcription elongation.
    Cancer Res. 2021 Jan 20. pii: 0008-5472.CAN-20-1968.
    PubMed     Abstract available

  24. HUNG RJ, Warkentin MT, Brhane Y, Chatterjee N, et al
    Assessing Lung Cancer Absolute Risk Trajectory based on a Polygenic Risk Model.
    Cancer Res. 2021 Jan 20. pii: 0008-5472.CAN-20-1237.
    PubMed     Abstract available

  25. KOLAPALLI SP, Sahu R, Chauhan NR, Jena KK, et al
    RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.
    Cancer Res. 2021;81:315-331.
    PubMed     Abstract available

  26. KAMIYAMA M, Augustin HG
    Alternatively Spliced Form of Angiopoietin-2 as a New Vascular Rheostat.
    Cancer Res. 2021;81:35-37.
    PubMed     Abstract available

  27. KAPIAINEN E, Kihlstrom MK, Pietila R, Kaakinen M, et al
    The Amino-Terminal Oligomerization Domain of Angiopoietin-2 Affects Vascular Remodeling, Mammary Gland Tumor Growth, and Lung Metastasis in Mice.
    Cancer Res. 2021;81:129-143.
    PubMed     Abstract available

  28. JEONG GY, Park MK, Choi HJ, An HW, et al
    NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
    Cancer Res. 2021;81:77-90.
    PubMed     Abstract available

    December 2020
  29. LA FLEUR L, Botling J, He F, Pelicano C, et al
    Targeting MARCO and IL-37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function.
    Cancer Res. 2020 Dec 8. pii: 0008-5472.CAN-20-1885.
    PubMed     Abstract available

  30. GARG R, Cooke M, Benavides F, Abba MC, et al
    PKCepsilon Is Required for KRAS-Driven Lung Tumorigenesis.
    Cancer Res. 2020;80:5166-5173.
    PubMed     Abstract available

  31. DOUGLASS SM, Fane ME, Sanseviero E, Ecker BL, et al
    Myeloid-derived suppressor cells are a major source of Wnt5A in the melanoma microenvironment and depend on Wnt5A for full suppressive activity.
    Cancer Res. 2020 Dec 1. pii: 0008-5472.CAN-20-1238.
    PubMed     Abstract available

    November 2020
  32. SHEN M, Xie S, Rowicki M, Michel S, et al
    Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-1876.
    PubMed     Abstract available

  33. CHUANG CH, Dorsch M, Dujardin P, Silas S, et al
    Altered mitochondria functionality defines a metastatic cell state in lung cancer and creates an exploitable vulnerability.
    Cancer Res. 2020 Nov 25. pii: 0008-5472.CAN-20-1865.
    PubMed     Abstract available

  34. GUO W, Li K, Sun B, Xu D, et al
    Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer.
    Cancer Res. 2020 Nov 23. pii: 0008-5472.CAN-20-0617.
    PubMed     Abstract available

  35. HARRISON EB, Porrello A, Bowman BM, Belanger AR, et al
    A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking.
    Cancer Res. 2020;80:4972-4985.
    PubMed     Abstract available

  36. SOOTOME H, Fujita H, Ito K, Ochiiwa H, et al
    Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Cancer Res. 2020;80:4986-4997.
    PubMed     Abstract available

  37. MCCLATCHY DM, Willers H, Hata AN, Piotrowska Z, et al
    Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
    Cancer Res. 2020;80:5121-5133.
    PubMed     Abstract available

  38. TAGAL V, Roth MG
    Loss of Aurora kinase signaling allows lung cancer cells to adopt endoreplication and form polyploid giant cancer cells that resist antimitotic drugs.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1693.
    PubMed     Abstract available

  39. SUN Y, Meyers BA, Czako B, Leonard P, et al
    Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
    Cancer Res. 2020;80:4840-4853.
    PubMed     Abstract available

    October 2020
  40. LIU CH, Chen Z, Chen K, Liao FT, et al
    Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy.
    Cancer Res. 2020 Oct 29. pii: 0008-5472.CAN-20-1994.
    PubMed     Abstract available

  41. WILLS CA, Liu X, Chen L, Zhao Y, et al
    Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1976.
    PubMed     Abstract available

  42. SU Y, Zhang X, Bidlingmaier S, Behrens CR, et al
    ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen.
    Cancer Res. 2020;80:4552-4564.
    PubMed     Abstract available

  43. WONG CC, Baum J, Silvestro A, Beste MT, et al
    Inhibition of IL-1beta by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-19-3176.
    PubMed     Abstract available

  44. SHANI O, Vorobyov T, Monteran L, Lavie D, et al
    Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type-2 immunity.
    Cancer Res. 2020 Oct 6. pii: 0008-5472.CAN-20-2116.
    PubMed     Abstract available

  45. SANCHEZ-MAGRANER L, Miles J, Baker CL, Applebee CJ, et al
    High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Cancer Res. 2020;80:4244-4257.
    PubMed     Abstract available

  46. EL-NIKHELY N, Karger A, Sarode P, Singh I, et al
    Metastasis-Associated Protein 2 Represses NF-kappaB to Reduce Lung Tumor Growth and Inflammation.
    Cancer Res. 2020;80:4199-4211.
    PubMed     Abstract available

  47. PULIDO I, Ollosi S, Aparisi S, Becker JH, et al
    Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
    Cancer Res. 2020;80:4224-4232.
    PubMed     Abstract available

    September 2020
  48. BELLERI M, Paganini G, Coltrini D, Ronca R, et al
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-3382.
    PubMed     Abstract available

  49. KIM KB, Kim Y, Rivard CJ, Kim DW, et al
    FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer.
    Cancer Res. 2020 Sep 24. pii: 0008-5472.CAN-20-1453.
    PubMed     Abstract available

    The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
    Cancer Res. 2020;80:3799-3802.
    PubMed     Abstract available

  51. GUPTA M, Concepcion CP, Fahey CG, Keshishian H, et al
    BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
    Cancer Res. 2020;80:3841-3854.
    PubMed     Abstract available

  52. GHERGUROVICH JM, Esposito M, Chen Z, Wang JZ, et al
    Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis.
    Cancer Res. 2020;80:3820-3829.
    PubMed     Abstract available

  53. LU Y, Liu Y, Oeck S, Zhang GJ, et al
    Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway.
    Cancer Res. 2020 Sep 1. pii: 0008-5472.CAN-20-1192.
    PubMed     Abstract available

  54. GHOSH P, Guo Y, Ashrafi A, Chen J, et al
    Oxygen-Enhanced Optoacoustic Tomography Reveals the Effectiveness of Targeting Heme and Oxidative Phosphorylation at Normalizing Tumor Vascular Oxygenation.
    Cancer Res. 2020;80:3542-3555.
    PubMed     Abstract available

    August 2020
  55. KUO MH, Lee AC, Hsiao SH, Lin SE, et al
    Crosstalk between SOX2 and TGF-beta signaling regulates EGFR-TKI tolerance and lung cancer dissemination.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-19-3228.
    PubMed     Abstract available

  56. HAYASHI M, Kuga A, Suzuki M, Panda H, et al
    Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
    Cancer Res. 2020;80:3331-3344.
    PubMed     Abstract available

  57. SHOLL LM, Oxnard GR, Paweletz CP
    Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy.
    Cancer Res. 2020;80:3197-3199.
    PubMed     Abstract available

  58. ZHANG Y, Cedervall J, Hamidi A, Herre M, et al
    Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis.
    Cancer Res. 2020;80:3345-3358.
    PubMed     Abstract available

  59. IRURZUN-ARANA I, McDonald TO, Troconiz IF, Michor F, et al
    Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
    Cancer Res. 2020;80:3372-3382.
    PubMed     Abstract available

  60. LI Y, Zhang X, Zhu S, Dejene EA, et al
    HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma.
    Cancer Res. 2020;80:3265-3278.
    PubMed     Abstract available

  61. QIU Z, Fa P, Liu T, Prasad CB, et al
    A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Cancer Res. 2020;80:3305-3318.
    PubMed     Abstract available

  62. SHAKED MS, Dassa B, Sinha S, Di Agostino S, et al
    A division of labor between YAP and TAZ in non-small cell lung cancer.
    Cancer Res. 2020 Aug 14. pii: 0008-5472.CAN-20-0125.
    PubMed     Abstract available

    July 2020
  63. ZHENG X, Weigert A, Reu S, Guenther S, et al
    Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small-Cell Lung Carcinoma.
    Cancer Res. 2020 Jul 22. pii: 0008-5472.CAN-20-0069.
    PubMed     Abstract available

  64. KOGLER M, Tortola L, Negri GL, Leopoldi A, et al
    HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
    Cancer Res. 2020;80:3009-3022.
    PubMed     Abstract available

  65. BRIDGES AE, Ramachandran S, Pathania R, Parwal U, et al
    RAD51AP1 deficiency reduces tumor growth by targeting stem cell self-renewal.
    Cancer Res. 2020 Jul 14. pii: 0008-5472.CAN-19-3713.
    PubMed     Abstract available

  66. LI F, Ng WL, Luster TA, Hu H, et al
    Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer.
    Cancer Res. 2020 Jul 9. pii: 0008-5472.CAN-19-3782.
    PubMed     Abstract available

  67. BAUMEISTER SE, Leitzmann MF, Bahls M, Meisinger C, et al
    Physical activity does not lower the risk of lung cancer.
    Cancer Res. 2020 Jul 9. pii: 0008-5472.CAN-20-1127.
    PubMed     Abstract available

  68. DAI C, Charlestin V, Wang M, Walker ZT, et al
    Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer.
    Cancer Res. 2020 Jul 6. pii: 0008-5472.CAN-19-2269.
    PubMed     Abstract available

  69. BROWNMILLER T, Juric JA, Ivey AD, Harvey BM, et al
    Y Chromosome LncRNA are involved in Radiation Response of Male Non-Small Cell Lung Cancer Cells.
    Cancer Res. 2020 Jul 2. pii: 0008-5472.CAN-19-4032.
    PubMed     Abstract available

  70. DIMITRAKOPOULOS FD, Kottorou AE, Kalofonou M, Kalofonos HP, et al
    The Fire Within: NF-kappaB involvement in Non-Small Cell Lung Cancer.
    Cancer Res. 2020 Jul 2. pii: 0008-5472.CAN-19-3578.
    PubMed     Abstract available

  71. BUI NHB, Napoli M, Davis AJ, Abbas HA, et al
    Spatiotemporal Regulation of DeltaNp63 by TGFbeta-Regulated miRNAs Is Essential for Cancer Metastasis.
    Cancer Res. 2020;80:2833-2847.
    PubMed     Abstract available

    June 2020
  72. ZHOU ZW, Ambrogio C, Bera AK, Li Q, et al
    KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0448.
    PubMed     Abstract available

  73. YANG YC, Pan KF, Lee WJ, Chang JH, et al
    Circulating proteoglycan endocan mediates EGFR-driven progression of non-small cell lung cancer.
    Cancer Res. 2020 Jun 19. pii: 0008-5472.CAN-20-0005.
    PubMed     Abstract available

  74. VANDAMME N, Denecker G, Bruneel K, Blancke G, et al
    The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype.
    Cancer Res. 2020 Jun 5. pii: 0008-5472.CAN-19-2373.
    PubMed     Abstract available

  75. ZHANG Y, Shi J, Liu X, Xiao Z, et al
    H2A Monoubiquitination Links Glucose Availability to Epigenetic Regulation of the Endoplasmic Reticulum Stress Response and Cancer Cell Death.
    Cancer Res. 2020;80:2243-2256.
    PubMed     Abstract available

  76. CHO J, Lee HJ, Hwang SJ, Min HY, et al
    The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression.
    Cancer Res. 2020;80:2257-2272.
    PubMed     Abstract available

  77. CHEN CW, Fu M, Du ZH, Zhao F, et al
    Long Noncoding RNA MRPL23-AS1 Promoteoid Cystic Carcinoma Lung Metastasis.
    Cancer Res. 2020;80:2273-2285.
    PubMed     Abstract available

    May 2020
    Artificial Intelligence Will Not Replace Health Professionals, but the Proper Use of Artificial Intelligence Will Make Health Professionals Better.
    Cancer Res. 2020;80:1912-1913.
    PubMed     Abstract available

  79. STARRETT JH, Guernet AA, Cuomo ME, Poels KE, et al
    Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
    Cancer Res. 2020;80:2017-2030.
    PubMed     Abstract available

    April 2020
  80. CHU W, Zhang X, Qi L, Fu Y, et al
    The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer.
    Cancer Res. 2020 Apr 20. pii: 0008-5472.CAN-19-3326.
    PubMed     Abstract available

  81. ZHAO H, Iqbal NJ, Sukrithan V, Nicholas C, et al
    Targeted inhibition of the E3 ligase SCF-Skp2/Cks1 has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC).
    Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-2400.
    PubMed     Abstract available

  82. YANG L, So JY, Skrypek N, Yang HH, et al
    Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization.
    Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3339.
    PubMed     Abstract available

    March 2020
  83. ROGERS RF, Walton MI, Cherry DL, Collins I, et al
    CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells.
    Cancer Res. 2020 Mar 11. pii: 0008-5472.CAN-19-1372.
    PubMed     Abstract available

  84. ZONG D, Gu J, Cavalcante GC, Yao W, et al
    BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1.
    Cancer Res. 2020 Mar 10. pii: 0008-5472.CAN-19-3674.
    PubMed     Abstract available

  85. MENDER I, Batten K, Peyton M, Vemula A, et al
    SLC43A3 Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2'-Deoxyguanosine.
    Cancer Res. 2020;80:929-936.
    PubMed     Abstract available

  86. KARKI K, Wright GA, Mohankumar K, Jin UH, et al
    A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
    Cancer Res. 2020;80:1011-1023.
    PubMed     Abstract available

  87. BRINKER AE, Vivian CJ, Beadnell TC, Koestler DC, et al
    Mitochondrial Haplotype of the Host Stromal Microenvironment Alters Metastasis in a Non-cell Autonomous Manner.
    Cancer Res. 2020;80:1118-1129.
    PubMed     Abstract available

    February 2020
  88. MARQUES M, Tranchant R, Risa-Ebri B, Suarez-Solis ML, et al
    Combined MEK and PI3K/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
    Cancer Res. 2020;80:843-856.
    PubMed     Abstract available

  89. JING B, Wang T, Sun B, Xu J, et al
    IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
    Cancer Res. 2020;80:784-797.
    PubMed     Abstract available

  90. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
    Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
    Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
    PubMed     Abstract available

  91. KONG T, Ahn R, Yang K, Zhu X, et al
    CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Cancer Res. 2020;80:444-457.
    PubMed     Abstract available

    January 2020
  92. TAVERNA JA, Hung CN, DeArmond DT, Chen M, et al
    Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Cancer Res. 2020 Jan 28. pii: 0008-5472.CAN-19-3183.
    PubMed     Abstract available

  93. CRISTEA S, Coles GL, Hornburg D, Gershkovitz M, et al
    The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-1027.
    PubMed     Abstract available

  94. IKEMORI R, Gabasa M, Duch P, Vizoso M, et al
    Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma.
    Cancer Res. 2020;80:276-290.
    PubMed     Abstract available

  95. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Computational staining of pathology images to study the tumor microenvironment in lung cancer.
    Cancer Res. 2020 Jan 8. pii: 0008-5472.CAN-19-1629.
    PubMed     Abstract available

    November 2019
  96. HAVEL JJ
    MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks.
    Cancer Res. 2019;79:5699-5701.
    PubMed     Abstract available

  97. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed     Abstract available

  98. UMEH-GARCIA M, Simion C, Ho PY, Batra N, et al
    A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.
    Cancer Res. 2019 Nov 6. pii: 0008-5472.CAN-19-0656.
    PubMed     Abstract available

    October 2019
  99. CHEN G, Park D, Magis AT, Behera M, et al
    Mcl-1 interacts with Akt to promote lung cancer progression.
    Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-0950.
    PubMed     Abstract available

  100. CHIOU J, Chang YC, Tsai HF, Lin YF, et al
    Follistatin-like protein 1 inhibits lung cancer metastasis by preventing proteolytic activation of osteopontin.
    Cancer Res. 2019 Oct 25. pii: 0008-5472.CAN-19-0842.
    PubMed     Abstract available

    A Breath of Fresh Air: Opening up the Lung Cancer Genome.
    Cancer Res. 2019;79:4808-4810.
    PubMed     Abstract available

  102. DONG SH, Li W, Wang L, Hu J, et al
    Histone-related genes are hypermethylated in lung cancer and hypermethylated HIST1H4F could serve as a pan-cancer biomarker.
    Cancer Res. 2019 Oct 1. pii: 0008-5472.CAN-19-1019.
    PubMed     Abstract available

    Sequencing the Events That Mediate Progression of Premalignant Lung Lesions.
    Cancer Res. 2019;79:4811-4813.
    PubMed     Abstract available

  104. KRYSAN K, Tran LM, Grimes BS, Fishbein GA, et al
    The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
    Cancer Res. 2019;79:5022-5033.
    PubMed     Abstract available

    September 2019
  105. HO MY, Liang SM, Hung SW, Liang CM, et al
    Retraction: MIG-7 Controls COX-2/PGE2-Mediated Lung Cancer Metastasis.
    Cancer Res. 2019;79:4553.

    August 2019
  106. CHUANG HC, Chang CC, Teng CF, Hsueh CH, et al
    MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-19-1402.
    PubMed     Abstract available

  107. VARTANIAN S, Lee J, Klijn C, Gnad F, et al
    ERBB3 and IGF1R signaling are required for Nrf2-dependent growth in KEAP1-mutant lung cancer.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-18-2086.
    PubMed     Abstract available

    July 2019
  108. XIE M, Zheng H, Madan-Lala R, Dai W, et al
    MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.
    Cancer Res. 2019 Jul 30. pii: 0008-5472.CAN-19-0698.
    PubMed     Abstract available

  109. CHANG YC, Chiou J, Yang YF, Su CY, et al
    Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-18-4080.
    PubMed     Abstract available

  110. ZHENG ZQ, Li ZX, Zhou GQ, Lin L, et al
    Long non-coding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3.
    Cancer Res. 2019 Jul 22. pii: 0008-5472.CAN-19-0799.
    PubMed     Abstract available

    June 2019
  111. KAMAL Y, Schmit SL, Hoehn HJ, Amos CI, et al
    Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3945.
    PubMed     Abstract available

  112. ACHARYA S, Yao J, Li P, Zhang C, et al
    Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3803.
    PubMed     Abstract available

  113. WANG Z, Tu K, Xia L, Luo K, et al
    The Open Chromatin Landscape of Non-small Cell Lung Carcinoma.
    Cancer Res. 2019 Jun 17. pii: 0008-5472.CAN-18-3663.
    PubMed     Abstract available

  114. DAVALOS V, Esteller M
    Disruption of Long Noncoding RNAs Targets Cancer Hallmark Pathways in Lung Tumorigenesis.
    Cancer Res. 2019;79:3028-3030.
    PubMed     Abstract available

  115. SHAHABI S, Kumaran V, Castillo J, Cong Z, et al
    LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response.
    Cancer Res. 2019;79:3050-3062.
    PubMed     Abstract available

    May 2019
  116. SASAKI Y, Fujimori H, Hozumi M, Onodera T, et al
    Dysfunction of poly(ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-18-1037.
    PubMed     Abstract available

  117. SONG M, Ping Y, Zhang K, Yang L, et al
    Low-dose IFN-gamma induces tumor cell stemness in the tumor microenvironment of non-small cell lung cancer.
    Cancer Res. 2019 May 13. pii: 0008-5472.CAN-19-0596.
    PubMed     Abstract available

    April 2019
  118. KONDO Y
    Genome-Epigenome-Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells?
    Cancer Res. 2019;79:1751-1752.
    PubMed     Abstract available

  119. PAIDI SK, Diaz PM, Dadgar S, Jenkins SV, et al
    Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment.
    Cancer Res. 2019;79:2054-2064.
    PubMed     Abstract available

  120. BUSHNELL GG, Hardas TP, Hartfield RM, Zhang Y, et al
    Biomaterial Scaffolds Recruit an Aggressive Population of Metastatic Tumor Cells In Vivo.
    Cancer Res. 2019;79:2042-2053.
    PubMed     Abstract available

  121. LEWIS DM, Pruitt H, Jain N, Ciccaglione M, et al
    A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.
    Cancer Res. 2019;79:1981-1995.
    PubMed     Abstract available

  122. ZHAO J, Feng M, Liu D, Liu H, et al
    Antagonism between HtrA3 and TGF-beta1 Contributes to Metastasis in Non-small-cell Lung Cancer.
    Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-2507.
    PubMed     Abstract available

  123. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Abstract available

  124. VUONG L, Kouverianou E, Rooney CM, McHugh BJ, et al
    An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Cancer Res. 2019;79:1480-1492.
    PubMed     Abstract available

    March 2019
  125. SOHONI S, Ghosh P, Wang T, Kalainayakan SP, et al
    Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells.
    Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-2156.
    PubMed     Abstract available

  126. ZOU T, Meyerson M
    Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
    Cancer Res. 2019;79:1038-1040.
    PubMed     Abstract available

  127. UDYAVAR AR, Wooten DJ, Hoeksema M, Bansal M, et al
    Correction: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
    Cancer Res. 2019;79:1014.

    February 2019
    ATM Inhibition Sensitizes Tumors to High-Dose Irradiation.
    Cancer Res. 2019;79:704-705.
    PubMed     Abstract available

  129. FUKUDA K, Takeuchi S, Arai S, Katayama R, et al
    Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.
    Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-2052.
    PubMed     Abstract available

  130. YAN Y, Sun N, Wang H, Kobayashi M, et al
    Whole genome-derived tiled peptide arrays detect pre-diagnostic autoantibody signatures in non-small cell lung cancer.
    Cancer Res. 2019 Feb 5. pii: 0008-5472.CAN-18-1536.
    PubMed     Abstract available

  131. MURTUZA A, Bulbul A, Shen JP, Keshavarzian P, et al
    Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
    Cancer Res. 2019 Feb 4. pii: 0008-5472.CAN-18-1281.
    PubMed     Abstract available

  132. ROMAN M, Lopez I, Guruceaga E, Baraibar I, et al
    Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
    Cancer Res. 2019;79:625-638.
    PubMed     Abstract available

  133. NEEL DS, Allegakoen DV, Olivas V, Mayekar MK, et al
    Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
    Cancer Res. 2019;79:546-556.
    PubMed     Abstract available

    January 2019
  134. LI YP, Sin TK, Zhu JZ, Zhang G, et al
    p300 mediates muscle wasting in Lewis lung carcinoma.
    Cancer Res. 2019 Jan 31. pii: 0008-5472.CAN-18-1653.
    PubMed     Abstract available

  135. JIANG Y, Chen T, Wang T, Liang W, et al
    PAK4 phosphorylates fumarase and blocks TGF-beta-induced cell growth arrest in lung cancer cells.
    Cancer Res. 2019 Jan 25. pii: 0008-5472.CAN-18-2575.
    PubMed     Abstract available

  136. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
    Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
    PubMed     Abstract available

  137. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    PubMed     Abstract available

  138. FILIPCZAK PT, Leng S, Tellez CS, Do KC, et al
    p53-suppressed oncogene TET1 prevents cellular aging in lung cancer.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-1234.
    PubMed     Abstract available

  139. KOSSENKOV AV, Qureshi R, Dawany NB, Wickramasinghe J, et al
    A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Cancer Res. 2019;79:263-273.
    PubMed     Abstract available

  140. WERFEL TA, Elion DL, Rahman B, Hicks DJ, et al
    Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
    Cancer Res. 2019;79:171-182.
    PubMed     Abstract available

  141. YAN X, Zhang X, Wang L, Zhang R, et al
    Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
    Cancer Res. 2019;79:125-132.
    PubMed     Abstract available

    December 2018
  142. PHALLEN J, Leal A, Woodward BD, Forde PM, et al
    Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
    Cancer Res. 2018 Dec 20. pii: 0008-5472.CAN-18-1082.
    PubMed     Abstract available

  143. ANAGNOSTOU V, Forde PM, White JR, Niknafs N, et al
    Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer.
    Cancer Res. 2018 Dec 12. pii: 0008-5472.CAN-18-1127.
    PubMed     Abstract available

    November 2018
  144. LAN J, Sun L, Xu F, Liu L, et al
    M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer.
    Cancer Res. 2018 Nov 6. pii: 0008-5472.CAN-18-0014.
    PubMed     Abstract available

  145. WANG J, Wang D, Niu X, Wang Z, et al
    Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases.
    Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1086.
    PubMed     Abstract available

    October 2018
  146. EL KADI N, Wang L, Davis A, Korkaya H, et al
    The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer.
    Cancer Res. 2018 Oct 17. pii: 0008-5472.CAN-17-3370.
    PubMed     Abstract available

    August 2018
  147. HUANG F, Shi Q, Li Y, Xu L, et al
    HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
    Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
    PubMed     Abstract available

  148. ZHOU Y, Shurin GV, Zhong H, Bunimovich YL, et al
    Schwann cells augment cell spreading and metastasis of lung cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-1702.
    PubMed     Abstract available

  149. MARTIN-SANCHEZ JC, Lunet N, Gonzalez-Marron A, Lidon-Moyano C, et al
    Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide.
    Cancer Res. 2018;78:4436-4442.
    PubMed     Abstract available

    June 2018
  150. BROUWER AF, Eisenberg MC, Meza R
    Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence.
    Cancer Res. 2018;78:3386-3396.
    PubMed     Abstract available

    May 2018
  151. MEDER L, Schuldt P, Thelen M, Schmitt A, et al
    Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.
    Cancer Res. 2018 May 18. pii: 0008-5472.CAN-17-2176.
    PubMed     Abstract available

    April 2018
  152. HEIM L, Friedrich J, Engelhardt M, Trufa DI, et al
    NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development.
    Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3297.
    PubMed     Abstract available

  153. SU W, Feng S, Chen X, Yang X, et al
    Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer.
    Cancer Res. 2018 Apr 18. pii: 0008-5472.CAN-18-0222.
    PubMed     Abstract available

  154. LU YX, Ju HQ, Liu ZX, Chen DL, et al
    ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.
    Cancer Res. 2018;78:1972-1985.
    PubMed     Abstract available

    March 2018
  155. SILINA K, Soltermann A, Attar FM, Casanova R, et al
    Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Cancer Res. 2018;78:1308-1320.
    PubMed     Abstract available

    February 2018
  156. MAKINOSHIMA H, Umemura S, Suzuki A, Nakanishi H, et al
    Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
    Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-2109.
    PubMed     Abstract available

  157. DE S, Lindner DJ, Coleman C, Wildey G, et al
    The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-1920.
    PubMed     Abstract available

    January 2018
  158. CARONNI N, Simoncello F, Stafetta F, Guarnaccia C, et al
    Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer.
    Cancer Res. 2018 Jan 23. pii: 0008-5472.CAN-17-1307.
    PubMed     Abstract available

  159. DOPESO H, Jiao HK, Cuesta AM, Henze AT, et al
    PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1346.
    PubMed     Abstract available

  160. YANG Y, Leonard M, Zhang Y, Zhao D, et al
    HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
    Cancer Res. 2018;78:422-435.
    PubMed     Abstract available

  161. TIMANER M, Letko-Khait N, Kotsofruk R, Benguigui M, et al
    Therapy-educated mesenchymal stem cells enrich for tumor initiating cells.
    Cancer Res. 2018 Jan 4. pii: 0008-5472.CAN-17-1547.
    PubMed     Abstract available

  162. ARNST KE, Wang Y, Hwang DJ, Xue Y, et al
    A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Cancer Res. 2018;78:265-277.
    PubMed     Abstract available

    December 2017
  163. ADELAIYE-OGALA R, Budka J, Damayanti NP, Arrington J, et al
    EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Cancer Res. 2017;77:6651-6666.
    PubMed     Abstract available

    November 2017
  164. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Abstract available

  165. HOU P, Li L, Chen F, Chen Y, et al
    PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
    PubMed     Abstract available

  166. BYRD TT, Fousek K, Pignata A, Szot C, et al
    TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
    Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
    PubMed     Abstract available

  167. SIVAKUMAR S, Lucas FAS, McDowell TL, Lang W, et al
    Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
    Cancer Res. 2017;77:6119-6130.
    PubMed     Abstract available

  168. KWAK JW, Laskowski J, Li HY, McSharry MV, et al
    Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression.
    Cancer Res. 2017 Nov 8. pii: canres.0240.2017.
    PubMed     Abstract available

  169. WANG W, Huang L, Jin JY, Jolly S, et al
    IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
    Cancer Res. 2017 Nov 8. pii: canres.2995.2017.
    PubMed     Abstract available

  170. HUANG H, Zhang W, Pan Y, Gao Y, et al
    YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.
    Cancer Res. 2017;77:5769-5781.
    PubMed     Abstract available

  171. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Abstract available

    October 2017
  172. ZUO H, Ueland PM, Midttun O, Vollset SE, et al
    Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) link vitamin B6 catabolism and lung cancer risk.
    Cancer Res. 2017 Oct 25. pii: canres.1923.2017.
    PubMed     Abstract available

    September 2017
  173. KIDDER BL, He R, Wangsa D, Padilla-Nash HM, et al
    SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.
    Cancer Res. 2017 Sep 26. pii: canres.0828.2017.
    PubMed     Abstract available

  174. SHUKLA V, Rao M, Zhang H, Beers J, et al
    ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.
    Cancer Res. 2017 Sep 21. pii: canres.0570.2017.
    PubMed     Abstract available

  175. YAO M, Yu T, Zhao YJ, Hu Z, et al
    MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway.
    Cancer Res. 2017 Sep 18. pii: canres.0671.2017.
    PubMed     Abstract available

  176. LIU Y, Li Y, Wang X, Liu F, et al
    Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Cancer Res. 2017;77:5068-5076.
    PubMed     Abstract available

  177. MURLIDHAR V, Reddy RM, Fouladdel S, Zhao L, et al
    Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
    Cancer Res. 2017;77:5194-5206.
    PubMed     Abstract available

  178. MCFARLAND CD, Yaglom JA, Wojtkowiak JW, Scott JG, et al
    The Damaging Effect of Passenger Mutations on Cancer Progression.
    Cancer Res. 2017;77:4763-4772.
    PubMed     Abstract available

  179. KACHLER K, Bailer M, Heim L, Schumacher F, et al
    Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma.
    Cancer Res. 2017 Sep 7. pii: canres.3313.2016.
    PubMed     Abstract available

  180. TAKAGI S, Ishikawa Y, Mizutani A, Iwasaki S, et al
    LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Cancer Res. 2017;77:4652-4662.
    PubMed     Abstract available

    August 2017
  181. KASIRI S, Shao C, Chen B, Wilson AN, et al
    GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
    Cancer Res. 2017;77:4448-4459.
    PubMed     Abstract available

    July 2017
  182. TILL J, Yoon C, Kim BJ, Roby KC, et al
    Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression.
    Cancer Res. 2017 Jul 31. pii: canres.0061.2017.
    PubMed     Abstract available

  183. DU W, Xu X, Niu Q, Zhang X, et al
    Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
    Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
    PubMed     Abstract available

  184. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer.
    Cancer Res. 2017 Jul 18. pii: canres.3152.2016.
    PubMed     Abstract available

  185. COOPER JM, Ou YH, McMillan E, Vaden RM, et al
    TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
    Cancer Res. 2017 Jul 17. pii: canres.0829.2017.
    PubMed     Abstract available

  186. JERMYN M, Mercier J, Aubertin K, Desroches J, et al
    Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy.
    Cancer Res. 2017;77:3942-3950.
    PubMed     Abstract available

  187. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Abstract available

  188. CHAKRABARTI S, Michor F
    Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
    Cancer Res. 2017;77:3908-3921.
    PubMed     Abstract available

  189. NG KY, Chan LH, Chai S, Tong M, et al
    TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma.
    Cancer Res. 2017 Jul 3. pii: canres.3456.2016.
    PubMed     Abstract available

    June 2017
  190. RICHER AL, Cala JM, O'Brien K, Carson VM, et al
    WEE1 kinase inhibitor AZD1775 has pre-clinical efficacy in LKB1-deficient non-small cell lung cancer.
    Cancer Res. 2017 Jun 26. pii: canres.3565.2016.
    PubMed     Abstract available

  191. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Abstract available

  192. TRIPATHI SC, Fahrmann JF, Celiktas M, Aguilar M, et al
    MCAM mediates chemoresistance in small cell lung cancer via the PI3K/AKT/SOX2 signaling pathway.
    Cancer Res. 2017 Jun 23. pii: canres.2874.2016.
    PubMed     Abstract available

    May 2017
  193. RIOS VELAZQUEZ E, Parmar C, Liu Y, Coroller TP, et al
    Somatic mutations drive distinct imaging phenotypes in lung cancer.
    Cancer Res. 2017 May 31. pii: canres.0122.2017.
    PubMed     Abstract available

  194. YE M, Zhang Y, Zhang X, Zhang JB, et al
    Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
    Cancer Res. 2017 May 18. pii: canres.3470.2016.
    PubMed     Abstract available

  195. SEN T, Tong P, Stewart CA, Cristea S, et al
    CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.
    Cancer Res. 2017 May 10. pii: canres.3409.2016.
    PubMed     Abstract available

  196. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Abstract available

  197. SHARMA SK, Pourat J, Abdel-Atti D, Carlin SD, et al
    Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Cancer Res. 2017 May 9. pii: canres.0299.2017.
    PubMed     Abstract available

  198. PAILLER E, Oulhen M, Borget I, Remon J, et al
    Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
    Cancer Res. 2017;77:2222-2230.
    PubMed     Abstract available

    April 2017
  199. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
    SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
    Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
    PubMed     Abstract available

  200. ZHANG Y, Xu W, Guo H, Zhang Y, et al
    NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
    Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
    PubMed     Abstract available

  201. STEVENS LE, Cheung WKC, Adua SJ, Arnal-Estape A, et al
    Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.
    Cancer Res. 2017;77:1905-1917.
    PubMed     Abstract available

  202. WEN H, Chiu YF, Kuo MH, Lee KL, et al
    Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
    Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
    PubMed     Abstract available

  203. WALTER DM, Venancio OS, Buza EL, Tobias JW, et al
    Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
    Cancer Res. 2017;77:1719-1729.
    PubMed     Abstract available

    March 2017
  204. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Abstract available

    January 2017
  205. HAN SY, Ko A, Kitano H, Choi CH, et al
    Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
    Cancer Res. 2017;77:343-354.
    PubMed     Abstract available

  206. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
    A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
    Cancer Res. 2017;77:153-163.
    PubMed     Abstract available

  207. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
    PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
    Cancer Res. 2017;77:187-197.
    PubMed     Abstract available

  208. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
    The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
    Cancer Res. 2017;77:14-26.
    PubMed     Abstract available

    November 2016
  209. DOWER CM, Bhat N, Wang EW, Wang HG, et al
    Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
    PubMed     Abstract available

  210. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
    Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
    PubMed     Abstract available

    August 2016
  211. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
    RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
    Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
    PubMed     Abstract available

    April 2016
  212. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
    TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:1757-69.
    PubMed     Abstract available

  213. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
    Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Cancer Res. 2016;76:1746-56.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.